Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN), Twist Bioscience (TWST) and Biogen (BIIB) with bullish sentiments.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioMarin Pharmaceutical (BMRN)
In a report issued on May 22, Christopher Raymond from Raymond James maintained a Buy rating on BioMarin Pharmaceutical. The company’s shares closed last Friday at $54.09.
According to TipRanks.com, Raymond is a 3-star analyst with an average return of
Currently, the analyst consensus on BioMarin Pharmaceutical is a Moderate Buy with an average price target of $87.26, a 61.5% upside from current levels. In a report issued on May 15, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $75.00 price target.
See the top stocks recommended by analysts >>
Twist Bioscience (TWST)
In a report issued on May 22, Subbu Nambi from Guggenheim maintained a Buy rating on Twist Bioscience, with a price target of $60.00. The company’s shares closed last Friday at $60.57, close to its 52-week high of $60.90.
According to TipRanks.com, Nambi is a 5-star analyst with an average return of
Twist Bioscience has an analyst consensus of Strong Buy, with a price target consensus of $63.43, representing an 8.4% upside. In a report issued on May 22, TD Cowen also reiterated a Buy rating on the stock with a $68.00 price target.
Biogen (BIIB)
In a report issued on May 22, Mohit Bansal from Wells Fargo maintained a Buy rating on Biogen, with a price target of $250.00. The company’s shares closed last Friday at $193.76.
According to TipRanks.com, Bansal is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $218.76 average price target, which is a 14.8% upside from current levels. In a report issued on May 15, Evercore ISI also initiated coverage with a Buy rating on the stock.
Read More on BMRN:
Disclaimer & DisclosureReport an Issue
- BioMarin price target lowered to $111 from $116 at Canaccord
- Buy Rating Reaffirmed on BioMarin as Voxzogo Skeletal Disorder Opportunity Expands; $94 Price Target Maintained
- BioMarin’s Voxzogo meets endpoint in Phase 3 pediatric hypochondroplasia trial
- StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
- BioMarin price target lowered to $80 from $85 at BofA
